Towards an Original Anti-ASFV Vaccine: Cellular Immunity Induced by Extracellular Vesicles Engineered with ASFV Proteins
Authors:
- Francesco ManfrediFrancesco Manfredi
- Flavia FerrantelliFlavia Ferrantelli
- Chiara ChiozziniCCChiara Chiozzini
- Micaela DonniniMDMicaela Donnini
- Patrizia LeonePLPatrizia Leone
- Katherina PuglieseKPKatherina Pugliese
- Monica CagiolaMCMonica Cagiola
- Cecilia RighiCRCecilia Righi
- Stefano PetriniSPStefano Petrini
- Monica GiammarioliMGMonica Giammarioli
- Francesco FelizianiFFFrancesco Feliziani
- Maurizio FedericoMaurizio Federico
Open Access
Abstract
Background/Objectives: African Swine Fever (ASF) represents one of the most serious threats to animal health and global food security. The causative agent of ASF is the African swine fever virus (ASFV), a DNA virus belonging to the Asfarviridae family. Here, we describe ex vivo results for an original anti-ASFV vaccine approach based on the cellular immune response induced by extracellular vesicles (EVs) engineered to express four ASFV proteins. EV engineering was achieved by expressing a DNA vector encoding a biologically inactive HIV-1 Nef protein (Nefmut), which exhibits unusually high efficiency of incorporation into EVs, even when fused to foreign proteins. Previous studies have demonstrated that intramuscular injection of Nefmut-based vectors leads to the engineering of Evs, spontaneously released by muscle cells, and induction of antigen-specific CD8+ T cell immunity. Methods: We designed DNA vectors expressing the fusion products between Nefmut and each of the four ASFV structural proteins p30, p54, pp62, and p72. Engineered EVs were molecularly characterized by Western blot and nanotrack analysis, and their potential immunogenicity was assessed by priming and cross-presentation assays. Results: We assessed that the four fusion proteins were successfully expressed in transfected mammalian cells, with the release of valuable amounts of engineered EVs. When immature swine dendritic cells were challenged with the engineered EVs and then co-cultivated with autologous peripheral blood lymphocytes in priming assays, lymphocyte subpopulations specifically reacting against each ASFV antigen were elicited, as detected by an IFN-γ ELISpot assay. In addition, we provide evidence that the Nefmut-based fusion products incorporated into the engineered EVs can be cross-presented by professional antigen-presenting cells, leading to cross-priming of autologous lymphocytes. Conclusions: These results represent the best premise to go forward with experiments examining immunogenicity and antiviral efficiency in pigs.Keywords
All Related Versions
Funding Information
- Ministero della Salute (EC59)
This publication has 40 references indexed in Scilit:
- Advancement in the development of gene/protein-based vaccines against African swine fever virusCurrent Research in Microbial Sciences, 2024
- An Exosome‐Based Vaccine Platform Imparts Cytotoxic T Lymphocyte Immunity Against Viral AntigensBiotechnology Journal, 2018
- Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cellsJournal of Molecular Medicine, 2017
- A strategy of antigen incorporation into exosomes: Comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particlesVaccine, 2012
- Exosomes: Extracellular organelles important in intercellular communicationJournal of Proteomics, 2010
- Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluationVaccine, 2006
- Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological FluidsCurrent Protocols in Cell Biology, 2006
- Neutralizing antibodies to African swine fever virus proteins p30, p54, and p72 are not sufficient for antibody-mediated protectionVirology, 2004
- Detection of T-Cell Degranulation: CD107a and b2004
- Characterization of P30, a highly antigenic membrane and secreted protein of African Swine Fever VirusVirology, 1992